XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholder's Equity
6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
STOCKHOLDER’S EQUITY

NOTE 3 - STOCKHOLDER’S EQUITY

 

On January 20, 2023, the Company closed its offering (the “Offering”) of 6,725,147 units (“Units”) of the Company at a price of C$1.71 per Unit, including the units issued pursuant to the full exercise of the over-allotment option by the underwriters in the Offering (the “Underwriters”), for aggregate gross proceeds of approximately C$11,500,000 before deducting Offering expenses.

 

In connection with the closing of the Offering, the Company entered into a Warrant Indenture dated January 20, 2023 (the “Warrant Indenture”) with Endeavor Trust Corporation, as the warrant agent, pursuant to which the Company issued Warrants to purchase up to a maximum of 3,362,573 Warrant Shares. Each Warrant is exercisable at any time after January 20, 2023, and prior to January 20, 2026.

  

As compensation in connection to the Offering, the Company paid the Underwriters cash compensation equal to 5.0% of the aggregate gross proceeds of the Offering and issued to the Underwriters 336,257 common stock purchase warrants (the “Compensation Warrants”). Each Compensation Warrant is exercisable for one share of common stock (each, a “Compensation Warrant Share”) for a period of 12 months following the closing of the Offering at a price of C$1.71 per Compensation Warrant Share. 

 

Recent Sales of Unregistered Securities

 

On June 13, 2022, 7,800,000 shares of common stock of the Company (“Common Shares”) were issued for the purchase of CR Reward. See Note 2 for additional information.

 

In addition to the above, the Company issued the following common shares for the twelve months ending December 31, 2022, and six months ending June 30, 2023:

 

Options converted to common shares (none)

 

Warrants converted to common shares

 

Date   Shares      Price 
June-22   208,334   CAD   $1.80 

 

Preferred shares converted to common shares
 
Date  Shares 
May-22   677,084 

  

Convertible Preferred Stock

 

In August 2011, the Board of Directors designated 5,000,000 shares of Preferred Stock as Series A Preferred Stock. Each share of Series A Preferred Stock is convertible into one share of common stock at the option of the preferred holder. The Series A Preferred Stock is not entitled to receive dividends and does not possess redemption rights. The Company is prohibited from effecting the conversion of the Series A Preferred Stock to the extent that, as a result of the conversion, the holder of such shares would beneficially own more than 4.99% (or, if this limitation is waived by the holder upon no less than 61 days prior notice to us, 9.99%) in the aggregate of the issued and outstanding shares of our common stock. The holders of the Company’s Series A Preferred Stock are also entitled to certain liquidation preferences upon the liquidation, dissolution or winding up of the business of the Company.

 

In October 2012, the Board of Directors designated 5,000,000 shares of Preferred Stock as Series B Preferred Stock. In July 2016, the Board of Directors increased the total Series B Preferred Stock designated to 7,500,000. Each share of Series B Preferred Stock is convertible into one share of common stock at the option of the preferred holder. The Series B Preferred Stock is not entitled to receive dividends and does not possess redemption rights. The Company is prohibited from effecting the conversion of the Series B Preferred Stock to the extent that, as a result of the conversion, the holder of such shares would beneficially own more than 4.99% (which may be increased or waived upon no less than 61 days prior notice) in the aggregate of the issued and outstanding shares of our common stock. For a period of 24 months from the issue date, the holder of Series B Preferred Stock were entitled to price protection as determined in the subscription agreement. The Company has evaluated this embedded lower price issuance feature in accordance with ASC 815 and determined that it is clearly and closely related to the host contract and is therefore accounted for as an equity instrument.

 

On May 4, 2022, 677,084 shares of Series B Preferred Stock were converted shares of common stock. As of June 30, 2023, there were no Preferred Stock shares outstanding.

 

Common Stock Options

 

On February 22, 2021, the Company’s Board of Directors approved a new stock option plan (the “Plan”). The aggregate number of shares of common stock of the Company (a “Share”) that may be reserved for issuance pursuant to the Plan shall not exceed 10% of the number of Shares issued and outstanding from time to time.

 

In June 2022, the Company granted 350,000 options to an officer and an employee of the Company, pursuant to the terms of the Company’s Stock Option Plan. The Black Scholes option pricing model was used to estimate the aggregate fair value of the June 2022 options of $324,816 with the following inputs:

 

Options   Exercise Price  

Expected Life

  Volatility  

Risk Free

Interest Rate

 
350,000   C$2.50   3.5 years   83.7%   2.94%  

 

In August 2022, the Company granted 100,000 options to two employees of the Company, pursuant to the terms of the Company’s Stock Option Plan. The Black Scholes option pricing model was used to estimate the aggregate fair value of the August 2022 options of $99,021 with the following inputs:

 

Options   Exercise Price  

Expected Life

  Volatility  

Risk Free

Interest Rate

 
100,000   C$1.96   3.5 years   80.3%   3.14%  

 

Stock Option Repricing

 

Effective September 29, 2022, the Company’s board of directors repriced certain previously granted and still outstanding vested and unvested stock option awards under the Company’s Plan held by current employees, officers and directors. As a result, the exercise price for these awards was lowered to C$2.00 per share. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing, 4,541,667 vested and unvested stock options outstanding as of September 29, 2022, with original exercise prices of C$3.00, were repriced.

  

The repricing on September 29, 2022, resulted in incremental stock-based compensation expense of $480,250, of which $188,233 related to vested stock option awards and was expensed on the repricing date, and $292,017 related to unvested stock option awards is being amortized on a straight-line basis over the remaining vesting period of those awards ranging from 5 months to 23 months.

 

For the six months ended June 30, 2023, and 2022, the Company recognized share-based compensation expense related to the stock options of $718,123, and $910,418, respectively. The options are vested based on years of service, with certain options vested after two years and other options vested after three years.

 

Stock Option Activity

 

A summary of the stock options as of June 30, 2023, and changes during the periods are presented below:

 

           Weighted     
           Average     
       Weighted   Remaining     
       Average   Contractual   Aggregate 
   Number of   Exercise   Life   Intrinsic 
   Options   Price   (Years)   Value 
Balance at December 31, 2021   4,800,002   $        1.55    4.36   $29,817 
Exercised   0    0.00    0    0 
Issued   450,000   C$2.03    5.00    0 
Canceled   50,000   C$2.00    0    0 
Balance at December 31, 2022   5,200,002    1.56    3.45    57,468 
Exercised   0    0.00    0    0 
Issued   0    0.00    0    0 
Canceled   150,000    1.53    0    0 
Balance at June 30, 2023   5,050,002   $1.48    2.93   $8,400 
Options exercisable at June 30, 2023   3,658,335   $1.47    2.88   $8,400 

 

Total outstanding warrants of 34,701,615 as of June 30, 2023, were as follows:

 

   Warrants Issued   Total 
Warrants issued (includes expired warrants)   1,434,522    27,433,335    3,777,784    3,362,573    336,257    36,344,471 
Issued date   1/16/2020    10/26/2020    3/4/2021    1/20/2023    1/20/2023      
Expiration date   1/15/2022    10/26/2024    3/4/2024    1/20/2026    1/20/2024      
Exercise price (Canadian $)  $1.20   $1.80   $2.80   $2.30   $1.71      
Balance at December 31, 2021   216,076    27,433,335    3,777,784    0    0    31,427,195 
Exercised   0    208,334    0    0    0    208,334 
Issued   0    0    0    0    0    0 
Expired   216,076    0    0    0    0    216,076 
Balance at December 31, 2022   0    27,225,001    3,777,784    0    0    31,002,785 
Exercised   0    0    0    0    0    0 
Issued   0    0    0    3,362,573    336,257    3,698,830 
Expired   0    0    0    0    0    0 
Balance at June 30, 2023   0    27,225,001    3,777,784    3,362,573    336,257    34,701,615